F
Fluid Biomed
Developing an innovative brain stent to heal aneurysms
About Fluid Biomed
Fluid Biomed is at the forefront of medical innovation, developing a groundbreaking solution for the treatment of brain aneurysms. The company has designed the world's first hybrid polymer-metal flow-diverting stent, a revolutionary medical device aimed at curing this potentially deadly condition. This innovative stent is uniquely constructed using a combination of dissolving polymer and metal, providing a scaffold that promotes better healing and improved visualization of blood vessels. The device is engineered to be highly flexible, allowing for easy navigation through the delicate blood vessels of the brain using standard techniques familiar to physicians. The stent's design is particularly noteworthy for its ability to gradually integrate into the blood vessel wall after curing the aneurysm, leaving minimal long-term impact. This feature, coupled with the polymer's invisibility to x-rays and its eventual dissolution, significantly reduces interference with follow-up CT and MRI scans. As a result, patients are spared from undergoing invasive angiogram tests and do not require lifelong blood thinners. Fluid Biomed's stent works by slowing down blood flow inside the weakened area of the blood vessel, allowing the aneurysm to thrombose over time. This process effectively protects patients from the risk of rupture and stroke while maintaining normal blood flow to other areas of the brain. Laboratory data suggests that the unique construction of this hybrid polymer-metal stent provides excellent flow-diversion properties, matching or exceeding the performance of existing metal flow-diverters in the market. The company's commitment to patient safety, treatment efficacy, and physician ease-of-use is evident in their approach to product development. With a team comprising academic specialists and practicing neurosurgeons, Fluid Biomed is well-positioned to optimize their medical device for real-world application, potentially revolutionizing the treatment of brain aneurysms and significantly improving patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 77.4/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Neurology, Metal Stent Technology, Spinout, Sustainable Development Goals, Polymers, Start Alberta, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2024 | $27M | $108M | IAG Capital Partners · ShangBay Capital · METIS innovative · LifeArc Ventures | ↗ |
| SEED✓Equity / VC | Aug 2021 | $4.7M | $19M | Amino Capital · Wharton Alumni Angels of Silicon Valley · Threshold Impact · ShangBay Capital | ↗ |
Growth signals
Latest recorded traffic for Fluid Biomed is 1.9K monthly website visits, up 251.9% over the last three months. Fluid Biomed's team declined 2.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Fluid Biomed in the Calgary ecosystem
The Fluid Biomed office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed9 investors entered at this stage
Thin Air Labs
ShangBay Capital
METIS innovative
Amino Capital
Wharton Alumni Angels of Silicon Valley
Threshold Impact
UCeed Investment Funds
Bluesky Equities- ALAlabaster
Series A3 investors entered at this stage
Amplitude Ventures
IAG Capital Partners
LifeArc Ventures
Other known investors5 additional known investors
University of Calgary
Accelerate Fund
Creative Destruction Lab
Innovate Calgary
UCeed - University of Calgary
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Fluid Biomed on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Fluid Biomed’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









